Perspective Therapeutics Names New Chief Science Officer as Co-Founder Steps Back
Event summary
- Perspective Therapeutics appointed Paul Lyne, Ph.D., as Chief Science Officer on July 8, 2026.
- Co-founder Michael K. Schultz, Ph.D., transitioned to Senior Scientific Advisor role.
- Lyne brings over 25 years of oncology research experience from Merck KGaA.
- Schultz co-founded the company and served as Chief Science Officer previously.
The big picture
This leadership transition comes as Perspective Therapeutics advances its clinical-stage radiopharmaceutical programs, including treatments for neuroendocrine tumors, melanoma, and solid tumors. The move reflects a strategic shift toward scaling manufacturing capabilities and preparing for late-phase clinical development, aligning with broader industry trends in precision oncology.
What we're watching
- Pipeline Acceleration
- How Paul Lyne's experience will impact the pace of Perspective Therapeutics' clinical development programs.
- Scientific Governance
- Whether Michael Schultz's continued advisory role maintains continuity in scientific vision during the transition.
- Strategic Focus
- The extent to which Lyne's background in immuno-oncology and antibody-drug conjugates influences Perspective's therapeutic focus.
Related topics